917 related articles for article (PubMed ID: 30902161)
21. Cholinesterases: new roles in brain function and in Alzheimer's disease.
Giacobini E
Neurochem Res; 2003 Apr; 28(3-4):515-22. PubMed ID: 12675140
[TBL] [Abstract][Full Text] [Related]
22. 1,4-Substituted 4-(1H)-pyridylene-hydrazone-type inhibitors of AChE, BuChE, and amyloid-β aggregation crossing the blood-brain barrier.
Prinz M; Parlar S; Bayraktar G; Alptüzün V; Erciyas E; Fallarero A; Karlsson D; Vuorela P; Burek M; Förster C; Turunc E; Armagan G; Yalcin A; Schiller C; Leuner K; Krug M; Sotriffer CA; Holzgrabe U
Eur J Pharm Sci; 2013 Jul; 49(4):603-13. PubMed ID: 23643737
[TBL] [Abstract][Full Text] [Related]
23. In silico screening of glycogen synthase kinase-3β targeted ligands against acetylcholinesterase and its probable relevance to Alzheimer's disease.
Jabir NR; Shakil S; Tabrez S; Khan MS; Rehman MT; Ahmed BA
J Biomol Struct Dyn; 2021 Sep; 39(14):5083-5092. PubMed ID: 32588759
[TBL] [Abstract][Full Text] [Related]
24. Butyrylcholinesterase: an important new target in Alzheimer's disease therapy.
Greig NH; Lahiri DK; Sambamurti K
Int Psychogeriatr; 2002; 14 Suppl 1():77-91. PubMed ID: 12636181
[TBL] [Abstract][Full Text] [Related]
25. A review on cholinesterase inhibitors for Alzheimer's disease.
Anand P; Singh B
Arch Pharm Res; 2013 Apr; 36(4):375-99. PubMed ID: 23435942
[TBL] [Abstract][Full Text] [Related]
26. Multifunctional novel Diallyl disulfide (DADS) derivatives with β-amyloid-reducing, cholinergic, antioxidant and metal chelating properties for the treatment of Alzheimer's disease.
Manral A; Saini V; Meena P; Tiwari M
Bioorg Med Chem; 2015 Oct; 23(19):6389-403. PubMed ID: 26337018
[TBL] [Abstract][Full Text] [Related]
27. Acridine: A Scaffold for the Development of Drugs for Alzheimer's Disease.
Sharma A; Piplani P
Curr Top Med Chem; 2023; 23(13):1260-1276. PubMed ID: 36740790
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic Strategies Targeting Amyloid-β in Alzheimer's Disease.
Pinheiro L; Faustino C
Curr Alzheimer Res; 2019; 16(5):418-452. PubMed ID: 30907320
[TBL] [Abstract][Full Text] [Related]
29. Flavanone glycosides inhibit β-site amyloid precursor protein cleaving enzyme 1 and cholinesterase and reduce Aβ aggregation in the amyloidogenic pathway.
Ali MY; Jannat S; Edraki N; Das S; Chang WK; Kim HC; Park SK; Chang MS
Chem Biol Interact; 2019 Aug; 309():108707. PubMed ID: 31194956
[TBL] [Abstract][Full Text] [Related]
30. SLOH, a carbazole-based fluorophore, mitigates neuropathology and behavioral impairment in the triple-transgenic mouse model of Alzheimer's disease.
Wu X; Kosaraju J; Zhou W; Tam KY
Neuropharmacology; 2018 Mar; 131():351-363. PubMed ID: 29309769
[TBL] [Abstract][Full Text] [Related]
31. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
32. Current concepts on selected plant secondary metabolites with promising inhibitory effects against enzymes linked to Alzheimer's disease.
Orhan IE
Curr Med Chem; 2012; 19(14):2252-61. PubMed ID: 22414107
[TBL] [Abstract][Full Text] [Related]
33. Critical evaluation of current Alzheimer's drug discovery (2018-19) & futuristic Alzheimer drug model approach.
Dorababu A
Bioorg Chem; 2019 Dec; 93():103299. PubMed ID: 31586701
[TBL] [Abstract][Full Text] [Related]
34. Effects of cannabidiol interactions with Wnt/β-catenin pathway and PPARγ on oxidative stress and neuroinflammation in Alzheimer's disease.
Vallée A; Lecarpentier Y; Guillevin R; Vallée JN
Acta Biochim Biophys Sin (Shanghai); 2017 Oct; 49(10):853-866. PubMed ID: 28981597
[TBL] [Abstract][Full Text] [Related]
35. Biaryl scaffold-focused virtual screening for anti-aggregatory and neuroprotective effects in Alzheimer's disease.
Khalid S; Zahid MA; Ali H; Kim YS; Khan S
BMC Neurosci; 2018 Nov; 19(1):74. PubMed ID: 30424732
[TBL] [Abstract][Full Text] [Related]
36. Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer's disease.
Kazim SF; Iqbal K
Mol Neurodegener; 2016 Jul; 11(1):50. PubMed ID: 27400746
[TBL] [Abstract][Full Text] [Related]
37. The participation of insulin-like growth factor-binding protein 3 released by astrocytes in the pathology of Alzheimer's disease.
Watanabe K; Uemura K; Asada M; Maesako M; Akiyama H; Shimohama S; Takahashi R; Kinoshita A
Mol Brain; 2015 Dec; 8(1):82. PubMed ID: 26637371
[TBL] [Abstract][Full Text] [Related]
38. [Alzheimer disease: cellular and molecular aspects].
Octave JN
Bull Mem Acad R Med Belg; 2005; 160(10-12):445-9; discussion 450-1. PubMed ID: 16768248
[TBL] [Abstract][Full Text] [Related]
39. Insights of Valacyclovir in Treatment of Alzheimer's Disease: Computational Docking Studies and Scopolamine Rat Model.
Patel P; Faldu K; Borisa A; Bhatt H; Shah J
Curr Neurovasc Res; 2022; 19(3):344-357. PubMed ID: 36089794
[TBL] [Abstract][Full Text] [Related]
40. Diabetes mellitus and Alzheimer's disease: GSK-3β as a potential link.
Zhang Y; Huang NQ; Yan F; Jin H; Zhou SY; Shi JS; Jin F
Behav Brain Res; 2018 Feb; 339():57-65. PubMed ID: 29158110
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
